{"canonical":"https://abierto.us/vendors/atelerix-life-sciences-inc-td8nl4uwnvw8","key":"TD8NL4UWNVW8","name":"ATELERIX LIFE SCIENCES INC","uei":"TD8NL4UWNVW8","city":"CHARLOTTESVILLE","state":"VA","awards":1,"obligated":"-680885.00","notices_won":0,"top_agency_name":"Office of Assistant Secretary for Preparedness and Response","top_naics":"541715","cage":"8ZNE9","parent_name":"ATELERIX LIFE SCIENCES INC","also_known_as":[],"country":"USA","actions":1,"first_action":"2024-07-23","last_action":"2024-07-23","breakdowns":{"naics":[{"key":"541715","name":null,"awards":1,"obligated":"-680885.00"}],"places":[{"key":"VA","name":null,"awards":1,"obligated":"-680885.00"}],"agencies":[{"key":"7505","name":"Office of Assistant Secretary for Preparedness and Response","awards":1,"obligated":"-680885.00"}],"award_types":[{"key":"DEFINITIVE CONTRACT","name":null,"awards":1,"obligated":"-680885.00"}],"competition":[{"key":"COMPETED UNDER SAP","name":null,"awards":1,"obligated":"-680885.00"}],"product_service_codes":[{"key":"AN13","name":null,"awards":1,"obligated":"-680885.00"}]},"awards_list":[{"award_key":"CONT_AWD_75A50123C00053_7505_-NONE-_-NONE-","permalink":"https://www.usaspending.gov/award/CONT_AWD_75A50123C00053_7505_-NONE-_-NONE-/","piid":"75A50123C00053","parent_piid":null,"award_type":"DEFINITIVE CONTRACT","vendor_key":"TD8NL4UWNVW8","recipient_name":"ATELERIX LIFE SCIENCES INC","recipient_uei":"TD8NL4UWNVW8","recipient_cage":"8ZNE9","recipient_city":"CHARLOTTESVILLE","recipient_state":"VA","sub_name":"Office of Assistant Secretary for Preparedness and Response","office_name":"BARDA - ASPR / DAAPPO / BARDA DCMA","office_key":"o-75A501","first_action_date":"2024-07-23","last_action_date":"2024-07-23","actions":1,"obligated":"-680885.00","current_total_value":"68115.00","potential_total_value":"68115.00","naics":"541715","psc":"AN13","extent_competed":"COMPETED UNDER SAP","set_aside":"NO SET ASIDE USED.","offers_received":100,"description":"ATELERIX - THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO PLAN AND EXECUTE A PHASE 1A CLINICAL TRIAL (HEREAFTER REFERRED TO AS THE ?PHASE 1A TRIAL?) OF THE NOVEL SMALL MOLECULE ATLX-0199 IN 30 NORMAL HEALTHY SUBJECTS. THE GOAL OF THE CLINICAL TRIAL IS","method":null,"confidence":null,"evidence":null,"opportunity_key":null,"opportunity_title":null}],"awards_total":1,"awards_page":1,"won":[],"won_total":0,"solicitations_won":[]}